FDA issues draft guidance on marketing submissions for AI-enabled medical devices
The Food and Drug Administration issued draft guidance Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.
Related News Articles
Headline
Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares how one of the nation’s largest health systems is putting artificial intelligence into…
Headline
The National Institutes of Health Aug. 5 issued guidance to researchers on the use of artificial intelligence for the research application process. According…
Headline
The Joint Commission June 11 announced a new partnership with the Coalition for Health AI to help accelerate the development and adoption of best practices and…
Headline
The National Security Agency, Cybersecurity and Infrastructure Security Agency and international partners May 22 released guidance on securing data used for…
Headline
The Administration for Strategic Preparedness and Response May 15 announced it is launching four pharmaceutical manufacturing projects using artificial…
Headline
In this conversation, Aaron Lewandowski, M.D., emergency medicine physician and the emergency medicine stroke representative at Henry Ford West Bloomfield…